From: Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts
Number | Age at recruitment (years) | Years of follow-up | Incident BC | Crude incidence rate (/105 person-years) | Premenopausal | Postmenopausal | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ER+ | ER- | Indefinite | BC | ER+ | ER- | Indefinite | BC | ||||||
EPIC study | |||||||||||||
France | 68,707 | 51.5 | 14.7 | 3386 | 382 | 1232 | 323 | 221 | 1776 | 1150 | 254 | 206 | 1610 |
Italy | 27,851 | 52.0 | 15.0 | 1135 | 287 | 401 | 88 | 92 | 581 | 402 | 70 | 82 | 554 |
Spain | 20,298 | 50.2 | 16.7 | 556 | 171 | 164 | 43 | 92 | 299 | 148 | 38 | 71 | 257 |
UK | 35,349 | 52.3 | 16.1 | 1602 | 300 | 328 | 76 | 267 | 671 | 475 | 65 | 391 | 931 |
Netherlands | 22,601 | 54.8 | 15.0 | 975 | 305 | 206 | 35 | 143 | 384 | 333 | 55 | 203 | 591 |
Greece | 11,337 | 55.6 | 11.7 | 201 | 158 | 19 | 6 | 44 | 69 | 35 | 3 | 94 | 132 |
Germany | 22,085 | 52.6 | 11.6 | 743 | 322 | 198 | 52 | 49 | 299 | 308 | 73 | 63 | 444 |
Sweden | 9142 | 50.5 | 16.4 | 370 | 247 | 143 | 38 | 38 | 219 | 87 | 27 | 37 | 151 |
Denmark | 29,309 | 56.3 | 16.4 | 1887 | 428 | 257 | 61 | 100 | 418 | 921 | 207 | 341 | 1469 |
Norway | 34,651 | 48.0 | 14.1 | 1212 | 263 | 245 | 54 | 480 | 779 | 158 | 30 | 245 | 433 |
Total | 281,330 | 52.1 | 14.7 | 12,067 | 312 | 3193 | 776 | 1526 | 5495 | 4017 | 822 | 1733 | 6572 |
WHI study | 82,319 | 63.2 | 8.2 | 2951 | 457 | – | – | – | – | 2276 | 421 | 254 | 2951 |